NAS
ALNY icon

Nykredit A/S’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nykredit A/S’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
+51,208
New +$15.4M 0.05% 283

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Nykredit A/S's ALNY Position: Q2 2026 in Review

Nykredit A/S opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 51,208 shares worth $15.4M. The stake represents 0.05% of the portfolio and ranks #283 among its holdings.

587 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Nykredit A/S held 51,208 shares of Alnylam Pharmaceuticals worth $15.4M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.05% of Nykredit A/S's portfolio in Q2 2026, its #283 holding.
  • 587 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.